Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Aflutinib
2. Ast2818
3. Furmonertinib
4. Furmonertinib Mesylate
5. Ivesa
6. N-(2-(2-(dimethylamino)ethyl-methylamino)-5-((4-(1-methylindol-3-yl)pyrimidin-2-yl)amino)-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)prop-2-enamide
1. 1869057-83-9
2. Furmonertinib
3. Ast2818
4. Ast-2818
5. A49a7a5yn4
6. Ivesa
7. N-[2-[2-(dimethylamino)ethyl-methylamino]-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]-6-(2,2,2-trifluoroethoxy)pyridin-3-yl]prop-2-enamide
8. N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)acrylamide
9. 2-propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-5-((4-(1-methyl-1h-indol-3-yl)-2-pyrimidinyl)amino)-6-(2,2,2-trifluoroethoxy)-3-pyridinyl)-
10. Aflutinib
11. N-(2-(2-(dimethylamino)ethyl-methylamino)-5-((4-(1-methylindol-3-yl)pyrimidin-2-yl)amino)-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)prop-2-enamide
12. Alflutinib (pseudo Inn)
13. Unii-a49a7a5yn4
14. Furmonertinib [who-dd]
15. Chembl4297258
16. Schembl17490447
17. Gtpl10477
18. Bcp30339
19. Example 3 [us10072002b2]
20. Ex-a2868-1
21. Ac-36862
22. Hy-112870
23. Alflutinib;ast-2818;ast 2818;ask120067;ask 120067;ask-120067
| Molecular Weight | 568.6 g/mol |
|---|---|
| Molecular Formula | C28H31F3N8O2 |
| XLogP3 | 4.4 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 11 |
| Rotatable Bond Count | 11 |
| Exact Mass | g/mol |
| Monoisotopic Mass | g/mol |
| Topological Polar Surface Area | 100 |
| Heavy Atom Count | 41 |
| Formal Charge | 0 |
| Complexity | 865 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Protein Kinase Inhibitors
Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)
Drugs in Development
Details:
ICP-189 is a potent and selective oral allosteric inhibitor of SHP2, which is being evaluated in combiation with furmonertinib for the treatment of advanced or metastatic non-small cell lung cancer.
Lead Product(s): ICP-189,Furmonertinib
Therapeutic Area: Oncology Brand Name: ICP-189
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 28, 2024
Lead Product(s) : ICP-189,Furmonertinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
InnoCare Doses First Patient In Study Of ICP-189 Combined With Furmonertinib
Details : ICP-189 is a potent and selective oral allosteric inhibitor of SHP2, which is being evaluated in combiation with furmonertinib for the treatment of advanced or metastatic non-small cell lung cancer.
Product Name : ICP-189
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 28, 2024
Details:
Proceeds will support NDA approval for furmonertinib, a novel oral EGFR kinase inhibitor with broad activity across EGFR mutations.
Lead Product(s): Furmonertinib
Therapeutic Area: Oncology Brand Name: AST2818
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Goldman Sachs & Co
Deal Size: $175.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 25, 2024
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Goldman Sachs & Co
Deal Size : $175.0 million
Deal Type : Public Offering
ArriVent Announces Pricing of Upsized Initial Public Offering
Details : Proceeds will support NDA approval for furmonertinib, a novel oral EGFR kinase inhibitor with broad activity across EGFR mutations.
Product Name : AST2818
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 25, 2024
Details:
The net proceeds will be used for the clinical development of (furmonertinib), which focuses on EGFR mutant-selective tyrosine kinase inhibitors that are developed for NSCLC patients.
Lead Product(s): Furmonertinib
Therapeutic Area: Oncology Brand Name: AST2818
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Goldman Sachs & Co
Deal Size: $135.7 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 22, 2024
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Goldman Sachs & Co
Deal Size : $135.7 million
Deal Type : Public Offering
Arrivent Unveils $135M IPO Pricing to get Furmonertinib to FDA
Details : The net proceeds will be used for the clinical development of (furmonertinib), which focuses on EGFR mutant-selective tyrosine kinase inhibitors that are developed for NSCLC patients.
Product Name : AST2818
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 22, 2024
Details:
AST2818 (furmonertinib) is an oral, small molecule, highly brain-penetrant, pan-EGFR mutant inhibitor that targets both classical (exon 19 deletion and L858R) and atypical EGFR mutations, including exon 20 insertion mutations as well as HER2 exon 20 insertion mutations.
Lead Product(s): Furmonertinib
Therapeutic Area: Oncology Brand Name: AST2818
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 30, 2023
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AST2818 (furmonertinib) is an oral, small molecule, highly brain-penetrant, pan-EGFR mutant inhibitor that targets both classical (exon 19 deletion and L858R) and atypical EGFR mutations, including exon 20 insertion mutations as well as HER2 exon 20 inse...
Product Name : AST2818
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 30, 2023
Details:
ICP-189 is a potent and selective oral allosteric inhibitor of SHP2, developed by InnoCare for the treatment of solid tumors as a single agent and/or in combination in combination with furmonertinib, a highly brain-penetrant, broadly active mutation-selective EGFR inhibitor.
Lead Product(s): ICP-189,Furmonertinib
Therapeutic Area: Oncology Brand Name: ICP-189
Study Phase: IND EnablingProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 13, 2023
Lead Product(s) : ICP-189,Furmonertinib
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ICP-189 is a potent and selective oral allosteric inhibitor of SHP2, developed by InnoCare for the treatment of solid tumors as a single agent and/or in combination in combination with furmonertinib, a highly brain-penetrant, broadly active mutation-sele...
Product Name : ICP-189
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 13, 2023
Details:
Under the agreement, InnoCare and ArriVent will jointly evaluate the anti-tumor activity and safety of ICP-189, a novel SHP2 allosteric inhibitor, combined with furmonertinib, a highly brain-penetrant, broadly active mutation-selective EGFR inhibitor, in advanced NSCLC.
Lead Product(s): ICP-189,Furmonertinib
Therapeutic Area: Oncology Brand Name: ICP-189
Study Phase: IND EnablingProduct Type: Other Small Molecule
Sponsor: Arrivent
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 13, 2023
Lead Product(s) : ICP-189,Furmonertinib
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Arrivent
Deal Size : Undisclosed
Deal Type : Collaboration
InnoCare and ArriVent Announce Clinical Development Collaboration
Details : Under the agreement, InnoCare and ArriVent will jointly evaluate the anti-tumor activity and safety of ICP-189, a novel SHP2 allosteric inhibitor, combined with furmonertinib, a highly brain-penetrant, broadly active mutation-selective EGFR inhibitor, in...
Product Name : ICP-189
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 13, 2023
Details:
The net proceedings will be used to support pivotal Phase 3 and additional studies with the Company’s lead product candidate AST2818 (furmonertinib), a highly brain penetrant, mutant-specific EGFR kinase inhibitor.
Lead Product(s): Furmonertinib
Therapeutic Area: Oncology Brand Name: AST2818
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Sofinnova Investments
Deal Size: $155.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing March 27, 2023
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Sofinnova Investments
Deal Size : $155.0 million
Deal Type : Series B Financing
ArriVent Biopharma Closes $155 Million Oversubscribed Series B Financing
Details : The net proceedings will be used to support pivotal Phase 3 and additional studies with the Company’s lead product candidate AST2818 (furmonertinib), a highly brain penetrant, mutant-specific EGFR kinase inhibitor.
Product Name : AST2818
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 27, 2023
Details:
The licensed small-molecule antagonist of EGFR ABK3376 is a pre-clinical candidate developed by Abbisko Therapeutics' proprietary drug discovery platform, which is a novel, highly potent, selective, and brain-penetrating new-generation EGFR inhibitor.
Lead Product(s): ABK3376,Furmonertinib
Therapeutic Area: Oncology Brand Name: ABK3376
Study Phase: PreclinicalProduct Type: Other Small Molecule
Sponsor: Shanghai Allist Pharmaceuticals
Deal Size: $187.9 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 03, 2023
Lead Product(s) : ABK3376,Furmonertinib
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Shanghai Allist Pharmaceuticals
Deal Size : $187.9 million
Deal Type : Licensing Agreement
Shanghai's Abbisko Out-Licenses EGFR Candidate in Potentially Nine-Figure Deal
Details : The licensed small-molecule antagonist of EGFR ABK3376 is a pre-clinical candidate developed by Abbisko Therapeutics' proprietary drug discovery platform, which is a novel, highly potent, selective, and brain-penetrating new-generation EGFR inhibitor.
Product Name : ABK3376
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 03, 2023
Details:
AST2818 (furmonertinib) is an oral, small molecule, highly brain-penetrant, pan-EGFR mutant inhibitor that targets both classical (exon 19 deletion and L858R) and atypical EGFR mutations, including exon 20 insertion mutations as well as HER2 exon 20 insertion mutations.
Lead Product(s): Furmonertinib
Therapeutic Area: Oncology Brand Name: AST2818
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 07, 2022
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AST2818 (furmonertinib) is an oral, small molecule, highly brain-penetrant, pan-EGFR mutant inhibitor that targets both classical (exon 19 deletion and L858R) and atypical EGFR mutations, including exon 20 insertion mutations as well as HER2 exon 20 inse...
Product Name : AST2818
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 07, 2022
Details:
Allist Pharma received approval for furmonertinib in EGFR T790M mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) indications in China in March 2021.
Lead Product(s): Furmonertinib
Therapeutic Area: Oncology Brand Name: AST2818
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Hillhouse Capital Group
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing June 30, 2021
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Hillhouse Capital Group
Deal Size : $150.0 million
Deal Type : Series A Financing
Details : Allist Pharma received approval for furmonertinib in EGFR T790M mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) indications in China in March 2021.
Product Name : AST2818
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 30, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
76
PharmaCompass offers a list of Furmonertinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Furmonertinib manufacturer or Furmonertinib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Furmonertinib manufacturer or Furmonertinib supplier.
PharmaCompass also assists you with knowing the Furmonertinib API Price utilized in the formulation of products. Furmonertinib API Price is not always fixed or binding as the Furmonertinib Price is obtained through a variety of data sources. The Furmonertinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Furmonertinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Furmonertinib, including repackagers and relabelers. The FDA regulates Furmonertinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Furmonertinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Furmonertinib supplier is an individual or a company that provides Furmonertinib active pharmaceutical ingredient (API) or Furmonertinib finished formulations upon request. The Furmonertinib suppliers may include Furmonertinib API manufacturers, exporters, distributors and traders.
Furmonertinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Furmonertinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Furmonertinib GMP manufacturer or Furmonertinib GMP API supplier for your needs.
A Furmonertinib CoA (Certificate of Analysis) is a formal document that attests to Furmonertinib's compliance with Furmonertinib specifications and serves as a tool for batch-level quality control.
Furmonertinib CoA mostly includes findings from lab analyses of a specific batch. For each Furmonertinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Furmonertinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Furmonertinib EP), Furmonertinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Furmonertinib USP).
